Vertex Pharmaceuticals
Yesterday, January 30, 2025, Vertex Pharmaceuticals (VRTX) announced FDA approval of journavx™(suzetrigine), a First-in-Class treatment for adults with moderate-to-severe acute pain. Today, Vertex Announced the CASGEVY® Reimbursement Agreement for treating Sickle Cell Disease in England.
We start with the Approval of the JOURNAVX™ News
Yesterday, after the stock market closed, Vertex Pharmaceuticals announced that the  U . . .